Pegasys - medication with immunomodulatory effects.
The main active ingredient of Pegasys - peginterferon alfa-2a, providing antiproliferative (preventing cell proliferation) and antiviral effect.
Pegasys produced in the form of a solution for subcutaneous administration.
Pegasys treatment is prescribed for chronic hepatitis C in patients with compensated cirrhosis and those with the disease were found.
Good reviews of Pegasys, used in conjunction with Ribavirin those patients who had not been treated or received interferon-alpha, but the therapy was ineffective.
Pegasys can be assigned, and in chronic hepatitis B, discovered in adult patients with compensated liver disease, inflammation or fibrosis.
Pegasys Guide: how to use
The drug is administered subcutaneously in the thigh or abdominal wall once in 7 days.
In chronic hepatitis B throughout the year (48 weeks) was administered weekly for 180 mcg of Pegasys.
Patients who had not previously been treated for hepatitis B, chronic hepatitis C is also administered 180 mg medication.
Ribavirin, which is administered in conjunction with Pegasys is taken orally with meals. The dosage of this medication is chosen individually.
The duration of combination therapy is determined by the genotype of the virus. If detected genotype 1, and after a month of treatment is determined in the blood of HCV RNA, therapy lasts 48 weeks. With genotype 1 and low viral load, genotype and 4 (with the proviso that test RNA negative at week 4) treatment Pegasys can last 24 weeks.
Patients who had already passed therapy administered 180 mg drug 1 time per week. Pegasys also in this case combined with ribavirin, which is taken in a dosage of 1 mg per day if the patient's weight is less than 75 kg, and at a dosage of 1, 2 mg, if the patient's weight is greater than or equal to 75 kg.
If at 12 weeks of treatment the virus in the blood is still found, Pegasys treatment was stopped.
Patients who already were treated for hepatitis B, Pegasys taken during the year (48 weeks). The exceptions are patients who have discovered the genotype 1 and have not responded to treatment with interferon and ribavirin - therapy in this case lasts for 72 weeks.
For the treatment of co-infection with HIV - HCV (chronic hepatitis C) Pegasys administered in a dosage of 180 micrograms. Inject the medication once a week throughout the year (48 weeks). The duration of treatment of genotype independent.
The instructions Pegasys indicated that patients with end-stage renal failure showed a decrease in weekly dosage of the drug - 135 mg.
There are reviews of PEGASYS patients from taking it into old age and suffering from liver failure: determined that the correct dosage of medication for these groups of patients is not necessary.
Side effects of Pegasys
During treatment with Pegasys may develop bacterial or fungal infections, bronchitis, herpes, oral candidiasis, otitis externa, endocarditis, pneumonia, skin infections, anemia, pancytopenia, thrombocytopenia, sarcoidosis, rheumatoid arthritis, angioedema, hypothyroidism, diabetes mellitus, diabetic ketoacidosis , anorexia, dehydration, depression. Also, tumors can occur in the liver, insomnia, anxiety, nervousness, aggression, hallucinations, mental disorders, the deterioration of libido, dermatitis, dry skin, rash, increased sweating, eczema, muscle or joint pain, muscle cramps, kidney failure, impotence.
There are reviews of Pegasys, indicating that the drug may cause headache, worsening of concentration, impaired memory and taste sensations, tremor, paresthesia, fatigue, peripheral neuropathy, seizures, inflammation of the eye, blurred vision, corneal ulcers, earaches, hearing loss, palpitations, heart attack, tachycardia, angina pectoris, vasculitis, pericarditis, congestive heart failure, shortness of breath, coughing, swelling and nasal sinuses, sore throat, diarrhea, abdominal pain, nausea, vomiting, pancreatitis, bleeding in the gastrointestinal tract.
Also, there is evidence that the action of Pegasys may form fatty liver or begin cholangitis.
Pegasys for instructions are not prescribed for decompensated cirrhosis, decompensated severe cardiovascular disease, severe liver disease, autoimmune hepatitis, as well as nursing, pregnant women, children up to 3 years, in case of hypersensitivity to the genetically engineered drugs, alpha interferon and polyethylene glycol other components of Pegasys.